What’s inside a trove of Trump-era FDA emails To view this email as a web page,
click here Zero Johnson & Johnson COVID-19 vaccine doses set to ship next week as production holdup lingers With a new CMO and phase 3 data to hand, Humanigen eyes COVID-19 drug emergency filing by June FDA releases treasure trove of Trump administration emails from early days of COVID-19 crisis Pandemic accelerating employers' interest in voluntary benefits: WTW survey COVID-19 tracker: UK to ramp up vaccine rollout as variant looms; WHO asks countries to donate shots before vaccinating kids Featured Story | By Eric Sagonowsky Johnson & Johnson’s COVID-19 vaccine ran into a big setback in late March when U.S. officials paused the rollout to investigate rare blood clots. While that issue has been resolved with a new warning about the rare risk, the company’s shot is running into another type of pause—a lack of supply. read more |
| |
|---|
|
Top Stories By Ben Adams Humanigen is prepping its COVID-19 drug lenzilumab for an emergency use authorization with the FDA before the month’s end. read more By Beth Snyder Bulik What was going through the minds of the FDA officials during the earliest days of the COVID-19 pandemic? Thanks to hundreds of emails released by the FDA on Thursday—forced through the Freedom of Information Act—enquiring minds can find out. It's still just a glimpse, however, as quite a bit of the text copy, subject lines and emails are blacked out for confidentially reasons. read more By Paige Minemyer The pandemic has accelerated employers' interest in offering voluntary benefits such as hospital indemnity coverage to workers, a new survey shows. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The U.K. plans to accelerate its vaccine rollout as a coronavirus variant first identified in India, and likely more transmissible than previous strains, begins to spread across the nation. The World Health Organization is asking rich countries to donate vaccines before using them in children. And more headlines. read more |
|
